- Medicare drug price rule may target under-the-skin Keytruda and OpdivoFor 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.BioPharma Dive · 1mo ago↗ source
- Six leaders working on LGBTQ+ inclusion in biopharmaIt’s been a tough 18 months for the LGBTQ+ community. The American Civil Liberties Union tracked 530 anti-LGBTQ bills across dozens of states this year. Nearly 40% of US workers say ...Endpoints · 1mo ago↗ source
- Lilly scores early positive data for new JAK drugAcquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.BioPharma Dive